A,B. Body weights of the 1-wk study (Fig. 3A-D). C. Body weights for the 4-week and 8-week study (Fig. 3E-L). D. Liver gene expression of 1-wk treatment with PF-04991532. E-G. Plasma insulin of drug t
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
Objective To analyze the efficacy and safety of dexamethasone in the treatment of non-puerperal mastitis (NPM), providing a new idea for the treatment of NPM. Methods From August 1, 2017 to August 30,
